Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world study.
Yijia HuaWei LiNan JinDongyan CaiJie SunChunxiao SunFan YangXinyu WuXiang HuangBi-Yun WangYongmei YinPublished in: Therapeutic advances in medical oncology (2022)
Pyrotinib-based therapy has the potential to improve survival in patients with lapatinib-resistant HER2-positive metastatic breast cancer, including those with brain metastases. Pyrotinib could provide a clinically significant increase in PFS for patients who benefited from prior lapatinib.